Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

AXSM

0.00

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ: AXSM) with a Outperform and raises the price target from $306 to $316.